Post-stroke Aphasia
Conditions
Interventions
Cerebellar Stimulation Group:The combination therapy of cTBS on right cerebellum and SLT
Cerebral Stimulation Group:The combination therapy of cTBS on right cerebral hemisphere and SLT
Sham Stimulation Group:The combination therapy of sham cTBS on right cerebellum and SLT
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18 to 75 years; (2) Meet the diagnostic criteria for ischemic stroke (according to the 2018 guidelines of the Chinese Society of Neurology) or meet the diagnostic criteria for hemorrhagic stroke (according to the 2019 guidelines of the Chinese Society of Neurology); first-ever stroke occurrence; lesions located in the left hemisphere; disease duration =15 days and =6 months. (3) Non-fluent aphasia (speech fluency score: 0–4) diagnosed using the Chinese version of the Western Aphasia Battery with an Aphasia Quotient (AQ) <93.8; (4) Right-handed assessed by the Edinburgh Handedness Inventory; (5) Native Mandarin speakers with intact pre-stroke language function, had=6 years of formal education; (6) Written informed consent from all subjects who participated in the study.
Exclusion criteria
Exclusion criteria: (1) A lesion in the right cerebellum or the right cerebral hemisphere; (2) Complicated by any neuropsychiatric diseases, such as Parkinson's disease or dementia; (3) Inability to cooperate due to dysarthria (NIHSS 10 >= 2) , severe hearing impairment, visual impairment, cognitive impairment or altered consciousness (NIHSS 1a >= 1); (4) Complicated by severe cardiac, pulmonary, hepatic, or renal dysfunction, or other major systemic diseases; (5) Medications altering the level of cortical excitability (e.g., antiepileptics, neuroleptics or benzodiazepines); (6) Patients with severe depression, anxiety, or other mental illnesses that preclude trial compliance; (7) Contraindications for rTMS according to the safety guide-lines: presence of metallic foreign bodies or implanted electronic devices; (8) Any neuromodulation treatment (including TMS or tDCS) in the 3 months before enrollment; (9) History of alcohol or drug abuse, or other abnormalities rendering the patient unsuitable for the trial as assessed by investigators; (10) Female participants who are pregnant, lactating, or of reproductive age with intentions or potential for pregnancy during the study; (11) Concurrent enrollment in any other interventional study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Western Aphasia Battery;Resting-state functional magnetic resonance imaging data; | — |
Secondary
| Measure | Time frame |
|---|---|
| Boston Diagnostic Aphasia Examination Severity Rating;Token test;Stroke and Aphasia Quality of Life Scale-39 generic version; | — |
Countries
China
Contacts
Public ContactWang Qiang
The Affiliated Hospital of Qingdao University
Outcome results
None listed